¡¡¡¡»Æ°ßÁѿ׵ľÞϸ¶ÔÁÑ¿×ÓúºÏÓнϴóÓ°Ïì¡£2013Äê¾ÙÊÀ²£Á§Ì廯°ßÇ£ÒýС×齫OCT²â¶¨µÄ>400 ¦ÌmÕß³ÆÎª´óÁѿף¬²¿·ÖÑо¿ÕßʵÑé½ÓÄÉÄÚ½çĤ°ê·×ªÊÖÒÕ¶Ô´óIMH¾ÙÐÐÒ½ÖÎÒÔ̽ÌÖÊÇ·ñ¿ÉÌá*ÊÖÊõ ÂÊ£¬³ÉΪ½üÄêÀ´»Æ°ßÁÑ¿×ÊÖÊõµÄÑо¿ÈÈÃÅ¡£
¡¡¡¡ÄÚ½çĤ°ê·×ªÊõÊǽâ¾ö´óIMHµÄ Ñ¡Ôñô?±¾Ñо¿ÖÐͨ¹ýÄÚ½çĤ°þ³ýÍŽáµÑÕ븺ѹÎüÒý¸¨ÖúÁѿױպÏÊÖÒÕÒ½ÖÎ408 - 939 ¦ÌmµÄIMH£¬·¢Ã÷¸ÃÒªÁì¿ÉʹÁÑ¿×ÏòÐÄÐÔËõС£¬´Ó¶øÐÞ¸´Áѿס£±¾Ñо¿ÖÐËùÓл¼ÕßÊõºóÁѿ׾ù³ÊUÐͺÍVÐÍÓúºÏ£¬ÎÞ3ÐͺÍ4ÐÍÓúºÏÕß¡£Ñо¿·¢Ã÷£¬4ÐÍÓúºÏÕß¾Ö²¿RPEϸ°ûÍâòÉñ¾ÊÓÍøÄ¤²ãȱÈ磬¹ÊÊõºóÊÓÁ¦½Ï²î¡£ÓÐÑо¿Åú×¢£¬IMHÊõºó4ÐÍÓúºÏÕß±È Îª10% - 20%¡£±¾×黼ÑÛÊ×´ÎÊõºóÁÑ¿×δ±ÕºÏÕßÕ¼25%£¬ÓÉÓÚÏÖÔÚ³¤Ð§ÆøÌåȱ·¦£¬¹ÊÁÑ¿×Êõºóδ±ÕÊÊʱÐèʵʱÐв£Á§ÌåÄÚÎÞ¾ú¿ÕÆø×¢É䣬ҽÖκóÁѿ׾ù±ÕºÏ¡£ËµÃ÷ËäÈ»²£Á§ÌåÇиîÍŽá¿ÕÆøÌî³ä¿Éʹ´óIMHÓúºÏ£¬µ«¿ÕÆø³äÌîµÄÒ½ÖÎ ¿ÉÄܲ»Èç³¤Ð§ÆøÌ壬ͬʱ֤ʵҽÖδóIMH²¢²»ÐèÒª¾ÙÐкã¾Ã²£Á§ÌåÄÚ¹èÓÍÌî³ä¡£
¡¡¡¡ÖµµÃ×¢ÖØµÄÊÇ£¬Áѿ׾Þϸ²¢·ÇÊÇÓ°ÏìÊ×´ÎÊÖÊõ ÂÊµÄ Ôµ¹ÊÔÓÉ£¬ÄÚ½çĤ°þ³ýÊõµÄ¼¼ÇÉÒ²ÊÇÊÖÊõ³É°ÜµÄÒªº¦¡£ÓÐȤµÄÊÇ£¬PangµÈÔÚÊÓÍøÄ¤È«²ãÁÑ¿×Öз¢Ã÷Óлư߰å²ãÁÑ¿×Ïà¹ØµÄÊÓÍøÄ¤Ç°Ä¤ÔöÉú(lamellar hole-associated epiretinal proliferation, LHEP)¡£LHEPÊÇÊÓÍøÄ¤°å²ãÁÑ¿×ÍâòµÄ¡¢µ«²»Ç£ÀÊÓÍøÄ¤µÄÒ»ÖÖËðÉËÐÞ¸´×éÖ¯£¬¿ÉÔö½ø»Æ°ßÁÑ¿×ÓúºÏ¡£LHEPÔ´×ÔÁѿ״¦ÊÓÍøÄ¤µÄÖÐÐÄ²ã£¬ÑØ×é֯ȱËð²¿Î»¾ÁÑ¿×ÔµÔöÉúÖÁÊÓÍøÄ¤Äڲ㣬ÊÖÊõÖÐÄÚ½çĤµÄÏòÐÄÐÔ°þ³ý¿ÉºÜºÃµØ±£»¤LHEP£¬ÓÐÖúÓÚÁѿױßÑØµÄËɽ⣬´Ó¶øÊ¹Áѿױպϡ£
¡¡¡¡ÄÚ½çĤ°ê·×ªÊõºóÊÓÍøÄ¤Íâ²ã×éÖ¯µÄÐÞ¸´ÊÇ·ñÀûÓÚÊÓÍøÄ¤µÄ¹¦Ð§ £¬´Ó¶ø¸üºÃµØ »Æ°ßÇøÊÓ¹¦Ð§ÏÖÔÚ±¨µÀ½ÏÉÙ£¬±ðµÄÒ²ÉÐȱ·¦¶ÔÄÚ½çĤ°ê·×ªÊõÓëÄÚ½çĤ°þ³ýÊõÊõºóÊÓ¹¦Ð§Ð§¹û¾ÙÐнÏÁ¿µÄÎÄÏ××ÊÁÏ¡£PakµÈÑо¿·¢Ã÷£¬ÄÚ½çĤ°ê·×ªÊõºó²¢Î´ÊӲ쵽ÏÔ×ŵÄÊÓÍøÄ¤ELM¼°EZµÄÐÞ¸´¡£±¾Ñо¿ÖнÓÄɵÑÕ븨ÖúµÄÁѿױպÏÊÖÒÕ£¬ÊõÖпÉÊÓ²ìÁѿ׵ÄËõСºÍ±ÕºÏ£¬ÊõºóÔçÆÚ¾Í¿ÉÒÔÊӲ쵽ELMºÍEZȱËð¹æÄ£µÄËõС£¬ÊõºóÊÓÁ¦ÏÔ×ÅÌá*£¬ÌáÐѸÃÊõʽÓÐÖúÓڻư߹¦Ð§µÄ ¡£